Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$19.62 USD
+1.57 (8.70%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $19.72 +0.10 (0.51%) 6:50 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARCT 19.62 +1.57(8.70%)
Will ARCT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
Other News for ARCT
ARCT forms Bollinger Band Squeeze on September 18
Cathie Wood Invests $37M into Biotech Stocks, Trims Stake in KTOS, TEM, and ROKU Stocks
Shooting Star Candlestick appears for ARCT after 0.22% move
Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku
Cathie Wood Bets on AMD, Figma, Bullish, and Biotech Plays, Trims Tempus AI, Roku